Security key
21833P301
Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share (the "Shares") (CRBP)
CUSIP: 21833P301
Q4 2024 13F Holders as of 31 Dec 2024
- Security type / class
- Equity / Common Stock, par value $0.0001 per share (the "Shares")
- Total 13F shares
- 10,952,105
- Total 13F value
- $129,272,235
- Share change
- -685,356
- Put/Call ratio
- 12%
- SEC-reported price per share
- $11.80
- Number of holders
- 98
- Value change
- -$16,308,014
- Number of buys
- 45
- Number of sells
- 47
- Shares outstanding
- 18,532,780
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2024
Institutions
98
Top holders
10
CRBP full security history
Ownership snapshot
Full 13F holder table
Corbus Pharmaceuticals Holdings, Inc. SEC filings
Corbus Pharmaceuticals Holdings, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of CRBP - Corbus Pharmaceuticals Holdings, Inc. - Common Stock, par value $0.0001 per share (the "Shares") (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
Cormorant Asset Managemen...
Comparable rows
15/15
Latest evidence
30 Sep 2024
13F
13D/G
Lead comparable stake: 5.9%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 5.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
5.9%
Cormorant Asset Management, LP
13%
Octagon Capital Advisors LP
6%
BlackRock, Inc.
4.3%
VANGUARD GROUP INC
3.5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
Company · OrbiMed Capital LLC
|
5.9%
from 13D/G
|
$18,825,948
912,552 shares
|
— | 30 Sep 2024 |
| Cormorant Asset Management, LP |
13F
Company
|
13%
|
$48,996,250
2,375,000 shares
|
— | 30 Sep 2024 |
| Octagon Capital Advisors LP |
13F
Company
|
6%
|
$23,002,450
1,115,000 shares
|
— | 30 Sep 2024 |
| BlackRock, Inc. |
13F
Company
|
4.3%
|
$16,560,133
802,721 shares
|
— | 30 Sep 2024 |
| VANGUARD GROUP INC |
13F
Company
|
3.5%
|
$13,319,760
645,650 shares
|
— | 30 Sep 2024 |
| TANG CAPITAL MANAGEMENT LLC |
13F
Company
|
3.2%
|
$12,378,000
600,000 shares
|
— | 30 Sep 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
98
Shares
10,952,105
Rows available
98
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2024 vs Q3 2024 Across Filers
Q3 2024 holders
106
Q4 2024 holders
98
Holder diff
-8
| Investor | Q3 2024 Shares | Q4 2024 Shares | Share Diff | Share Chg % | Q3 2024 value | Q4 2024 value | Value change | Value Chg % |
|---|